LTS:0R0T (USA)
Business Description
Amgen Inc
NAICS : 325412
SIC : 2834
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Compare
Compare
Traded in other countries / regions
AMGN.Argentina
•
AMGN.Austria
•
AMGN34.Brazil
•
AMGN.Chile
•
AMG.Germany
•
04332.Hong Kong
•
AMGN.Italy
•
AMG N.Mexico
•
AMGN.Switzerland
•
0R0T.UK
•
AMGN.USA
Description
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | 0.04 | |||||
| Debt-to-Equity | 15.1 | |||||
| Debt-to-EBITDA | 3.01 | |||||
| Interest Coverage | 7.46 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 1.8 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | 0.6 | |||||
| 3-Year EPS without NRI Growth Rate | -6.6 | |||||
| 3-Year FCF Growth Rate | -2.7 | |||||
| 3-Year Book Growth Rate | -15.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 9.41 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 3.04 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.13 | |||||
| 9-Day RSI | 59.84 | |||||
| 14-Day RSI | 57.02 | |||||
| 6-1 Month Momentum % | 11.73 | |||||
| 12-1 Month Momentum % | 8.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.53 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 0.57 | |||||
| Days Inventory | 243.23 | |||||
| Days Sales Outstanding | 67.91 | |||||
| Days Payable | 73.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.96 | |||||
| Dividend Payout Ratio | 0.63 | |||||
| 3-Year Dividend Growth Rate | 10.1 | |||||
| Forward Dividend Yield % | 3.11 | |||||
| 5-Year Yield-on-Cost % | 5.17 | |||||
| 3-Year Average Share Buyback Ratio | 3.9 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.75 | |||||
| Operating Margin % | 35.47 | |||||
| Net Margin % | 24.92 | |||||
| ROE % | 124.08 | |||||
| ROA % | 10.8 | |||||
| ROIC % | 19.04 | |||||
| ROC (Joel Greenblatt) % | 159.77 | |||||
| ROCE % | 18.43 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.05 | |||||
| Forward PE Ratio | 14.04 | |||||
| PE Ratio without NRI | 21.05 | |||||
| Shiller PE Ratio | 23.47 | |||||
| Price-to-Owner-Earnings | 18.26 | |||||
| PEG Ratio | 4.48 | |||||
| PS Ratio | 5.23 | |||||
| PB Ratio | 54.93 | |||||
| Price-to-Free-Cash-Flow | 16.55 | |||||
| Price-to-Operating-Cash-Flow | 14.84 | |||||
| EV-to-EBIT | 18.55 | |||||
| EV-to-Forward-EBIT | 12.86 | |||||
| EV-to-EBITDA | 13.39 | |||||
| EV-to-Forward-EBITDA | 10.13 | |||||
| EV-to-Revenue | 6.15 | |||||
| EV-to-Forward-Revenue | 6.19 | |||||
| EV-to-FCF | 19.41 | |||||
| Price-to-Projected-FCF | 1.19 | |||||
| Price-to-DCF (Earnings Based) | 1.16 | |||||
| Price-to-DCF (FCF Based) | 0.78 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Earnings Yield (Greenblatt) % | 5.39 | |||||
| Forward Rate of Return (Yacktman) % | 9.51 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 26,384 | ||
| EPS (TTM) ($) | 11.8 | ||
| Beta | 0.27 | ||
| Volatility % | 20.48 | ||
| 14-Day RSI | 57.02 | ||
| 14-Day ATR ($) | 3.161347 | ||
| 20-Day SMA ($) | 247.86125 | ||
| 12-1 Month Momentum % | 8.8 | ||
| 52-Week Range ($) | 198.96 - 258.19 | ||
| Shares Outstanding (Mil) | 534.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amgen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||